Antioxidants (Basel):一种装载生姜提取物作为治疗鼻炎和鼻窦炎的绿色天然策略

2021-08-20 AlexYang MedSci原创

鼻炎和鼻窦炎是涉及上呼吸道的两种主要临床病症。它们在特应性状态、症状严重程度、持续时间、病史和病因方面有所不同,但有一些共同的临床表现,如粘膜炎症、打喷嚏、瘙痒、脓性鼻涕、鼻塞、面部压力和嗅觉丧失。此

鼻炎和鼻窦炎是涉及上呼吸道的两种主要临床病症。它们在特应性状态、症状严重程度、持续时间、病史和病因方面有所不同,但有一些共同的临床表现,如粘膜炎症、打喷嚏、瘙痒、脓性鼻涕、鼻塞、面部压力和嗅觉丧失。此外,由于上呼吸道粘膜感觉神经炎症,通常会出现对非过敏性的刺激,如冷空气和刺激物的高反应性。鼻窦炎涉及鼻腔粘膜以外的副鼻窦的炎症。过敏性鼻炎通常被认为与慢性鼻炎有因果关系。它们是严重的常见疾病,影响到全球15%到45%的人口,对患者的日常生活产生负面影响,尤其是那些症状严重和有重大残疾的患者。 近期,研究人员制造出了一种完全绿色的纳米技术鼻喷雾,并建议作为鼻炎和鼻窦炎的替代治疗方法。 该鼻喷雾是通过结合脂质体对屏障功能的强化作用、透明质酸钠的保湿和润滑特性以及生姜提取物的抗炎和抗氧化活性而制成的。研究人员将提取物装入透明质酸固定的特殊磷脂囊泡(hyalurosomes)中,并在水相中进一步富集甘油。同时,研究人员将脂质体和甘油体也制备出来作为参照。低温透射电子显微镜(cryo-TEM)观察证实,囊泡是低聚状态和多室的,尺寸小(~140纳米),带负电(~-23毫伏)。Spraytec®和即时图

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1009622, encodeId=7e711009622be, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c14c5561863, createdName=ms2000002024894779, createdTime=Fri Aug 20 08:04:08 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009594, encodeId=97b3100959485, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/b7a64c53cc944fed9f929b23bad22004/7f2fd5fb135d454e823fcf64fa76bd8f.jpg, createdBy=b07a5542322, createdName=nahsey, createdTime=Fri Aug 20 06:36:59 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009590, encodeId=1766100959070, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Fri Aug 20 04:27:40 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009588, encodeId=80ee100958802, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Aug 20 02:20:02 CST 2021, time=2021-08-20, status=1, ipAttribution=)]
    2021-08-20 ms2000002024894779

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1009622, encodeId=7e711009622be, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c14c5561863, createdName=ms2000002024894779, createdTime=Fri Aug 20 08:04:08 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009594, encodeId=97b3100959485, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/b7a64c53cc944fed9f929b23bad22004/7f2fd5fb135d454e823fcf64fa76bd8f.jpg, createdBy=b07a5542322, createdName=nahsey, createdTime=Fri Aug 20 06:36:59 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009590, encodeId=1766100959070, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Fri Aug 20 04:27:40 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009588, encodeId=80ee100958802, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Aug 20 02:20:02 CST 2021, time=2021-08-20, status=1, ipAttribution=)]
    2021-08-20 nahsey

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1009622, encodeId=7e711009622be, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c14c5561863, createdName=ms2000002024894779, createdTime=Fri Aug 20 08:04:08 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009594, encodeId=97b3100959485, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/b7a64c53cc944fed9f929b23bad22004/7f2fd5fb135d454e823fcf64fa76bd8f.jpg, createdBy=b07a5542322, createdName=nahsey, createdTime=Fri Aug 20 06:36:59 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009590, encodeId=1766100959070, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Fri Aug 20 04:27:40 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009588, encodeId=80ee100958802, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Aug 20 02:20:02 CST 2021, time=2021-08-20, status=1, ipAttribution=)]
    2021-08-20 涂涂0518

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1009622, encodeId=7e711009622be, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c14c5561863, createdName=ms2000002024894779, createdTime=Fri Aug 20 08:04:08 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009594, encodeId=97b3100959485, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/b7a64c53cc944fed9f929b23bad22004/7f2fd5fb135d454e823fcf64fa76bd8f.jpg, createdBy=b07a5542322, createdName=nahsey, createdTime=Fri Aug 20 06:36:59 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009590, encodeId=1766100959070, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/0144bfea4ffa499e849a2e74797b5fb2/bb75638200fd450e9511b0b3dd092ba8.jpg, createdBy=8d772453344, createdName=涂涂0518, createdTime=Fri Aug 20 04:27:40 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009588, encodeId=80ee100958802, content=不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Aug 20 02:20:02 CST 2021, time=2021-08-20, status=1, ipAttribution=)]
    2021-08-20 仁术2021

    不错学习了

    0

相关资讯

盘点:近期鼻炎与治疗进展(八)

【1】Ann Allergy Asthma Immunol:SLIT片剂治疗过敏性鼻炎的进展分析

Ear Nose Throat J:后鼻神经冷冻消融术对慢性鼻炎患者的症状和特定疾病的生活质量的影响

慢性鼻炎在美国影响了8000多万人,通过流行研究的推断,全世界受影响的人口大约有4.5亿。受这种疾病过程影响的人口规模使得可查的其对经济影响。在21世纪初,仅过敏性鼻炎(AR)就造成了超过30亿美元的

Eur Arch Otorhinolaryngol:通过互联网搜索检测腺样体肥大、鼻炎和过敏性鼻炎的流行病学的相关性

腺样体肥大(AH)是儿童阻塞性睡眠呼吸暂停(OSA)最常见的原因。AH的发病机制尚不清楚,但它与许多因素有关,如吸烟、季节性过敏和呼吸道感染。之前的研究已经证实了AH和鼻窦炎之间的关系,针对AH的治疗

盘点:近期鼻炎研究进展(九)

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期鼻炎的研究进展,与

盘点:近期鼻炎与治疗进展(九)

【1】Laryngoscope:成人鼻窦炎患者的免疫球蛋白替代疗法治疗结果

Allergy Asthma Proc:哮喘和鼻炎控制对工作效率和活动障碍的交互影响

有症状的哮喘和鼻炎对患者的工作效率和活动有负面影响。然而,人们对哮喘和鼻炎控制对工作效率和活动障碍的潜在交互影响知之甚少。